Orally Disintegrating Tablet Market By Drug Class (Anti-Epileptics, Anti-Psychotics, Anti-Hypertensives, Proton Pump Inhibitors, Other Drug Classes) By Disease Indication (CNS Diseases, CVS Disorders, GI Diseases, Other Disease Indications) By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Drug Stores) and by Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033

Published date: Jan 2024
Report ID: 13004
Number of Pages: 304
Format:

Fact Checked

Cite this Research

- 1. Orally Disintegrating Tablet Market Introduction
  - 1.1. Definition
  - 1.2. Taxonomy
  - 1.3. Research Scope
- 2. Executive Summary
  - 2.1. Key Findings by Major Segments
  - 2.2. Top strategies by Major Players
- 3. Global Orally Disintegrating Tablet Market Overview
  - 3.1. Orally Disintegrating Tablet Market Dynamics
    
    3.1.1. Drivers
    
    3.1.2. Opportunities
    
    3.1.3. Restraints
    
    3.1.4. Challenges
  - 3.2. PESTLE Analysis
  - 3.3. Opportunity Map Analysis
  - 3.4. PORTER'S Five Forces Analysis
  - 3.5. Market Competition Scenario Analysis
  - 3.6. Product Life Cycle Analysis
  - 3.7. Opportunity Orbits
  - 3.8. Manufacturer Intensity Map
- 4. Global Orally Disintegrating Tablet Market Value ((US$ Mn)), Share (%), and Growth Rate (%) Comparison by Type, 2012-2028
  - 4.1. Global Orally Disintegrating Tablet Market Analysis by Type: Introduction
  - 4.2. Market Size and Forecast by Region
  - 4.3. Anti-Psychotics Drug
  - 4.4. Anti-Epileptics Drug
  - 4.5. Other
- 5. Global Orally Disintegrating Tablet Market Value ((US$ Mn)), Share (%), and Growth Rate (%) Comparison by Application, 2012-2028
  - 5.1. Global Orally Disintegrating Tablet Market Analysis by Application: Introduction
  - 5.2. Market Size and Forecast by Region
  - 5.3. CNS Diseases
  - 5.4. Gastrointestinal Diseases
  - 5.5. CVS Diseases
  - 5.6. Other
- 6. Global Orally Disintegrating Tablet Market Value ((US$ Mn)), Share (%), and Growth Rate (%) Comparison by Region, 2012-2028
  - 6.1. North America
    
    6.1.1. North America Orally Disintegrating Tablet Market: Regional Trend Analysis
    
    6.1.1.1. US
    
    6.1.1.2. Canada
    
    6.1.1.3. Mexico
  - 6.2.1. Europe
    
    6.2.1. Europe Orally Disintegrating Tablet Market: Regional Trend Analysis
    
    6.2.1.1. Germany
    
    6.2.1.2. France
    
    6.2.1.3. UK
    
    6.2.1.4. Russia
    
    6.2.1.5. Italy
    
    6.2.1.6. Spain
    
    6.2.1.7. Rest of Europe
  - 6.3. Asia-Pacific
    
    6.3.1. Asia-Pacific Orally Disintegrating Tablet Market: Regional Trend Analysis
    
    6.3.1.1. China
    
    6.3.1.2. Japan
    
    6.3.1.3. Korea
    
    6.3.1.4. India
    
    6.3.1.5. Rest of Asia
  - 6.4. Latin America
    
    6.4.1. Latin America Orally Disintegrating Tablet Market: Regional Trend Analysis
    
    6.4.1.1. Brazil
    
    6.4.1.2. Argentina
    
    6.4.1.3. Rest of Latin America
  - 6.5. Middle East and Africa
    
    6.5.1. Middle East and Africa Orally Disintegrating Tablet Market: Regional Trend Analysis
    
    6.5.1.1. GCC
    
    6.5.1.2. South Africa
    
    6.5.1.3. Israel
    
    6.5.1.4. Rest of MEA
- 7. Global Orally Disintegrating Tablet Market Competitive Landscape, Market Share Analysis, and Company Profiles
  - 7.1. Market Share Analysis
  - 7.2. Company Profiles
  - 7.3. Teva
    
    7.3.1. Company Overview
    
    7.3.2. Financial Highlights
    
    7.3.3. Product Portfolio
    
    7.3.4. SWOT Analysis
    
    7.3.5. Key Strategies and Developments
  - 7.4. Merck
    
    7.4.1. Company Overview
    
    7.4.2. Financial Highlights
    
    7.4.3. Product Portfolio
    
    7.4.4. SWOT Analysis
    
    7.4.5. Key Strategies and Developments
  - 7.5. Mylan
    
    7.5.1. Company Overview
    
    7.5.2. Financial Highlights
    
    7.5.3. Product Portfolio
    
    7.5.4. SWOT Analysis
    
    7.5.5. Key Strategies and Developments
  - 7.6. Pfizer
    
    7.6.1. Company Overview
    
    7.6.2. Financial Highlights
    
    7.6.3. Product Portfolio
    
    7.6.4. SWOT Analysis
    
    7.6.5. Key Strategies and Developments
  - 7.7. Johnson and Johnson
    
    7.7.1. Company Overview
    
    7.7.2. Financial Highlights
    
    7.7.3. Product Portfolio
    
    7.7.4. SWOT Analysis
    
    7.7.5. Key Strategies and Developments
  - 7.8. GSK
    
    7.8.1. Company Overview
    
    7.8.2. Financial Highlights
    
    7.8.3. Product Portfolio
    
    7.8.4. SWOT Analysis
    
    7.8.5. Key Strategies and Developments
  - 7.9. Otsuka
    
    7.9.1. Company Overview
    
    7.9.2. Financial Highlights
    
    7.9.3. Product Portfolio
    
    7.9.4. SWOT Analysis
    
    7.9.5. Key Strategies and Developments
  - 7.10. Eli Lilly and Company
    
    7.10.1. Company Overview
    
    7.10.2. Financial Highlights
    
    7.10.3. Product Portfolio
    
    7.10.4. SWOT Analysis
    
    7.10.5. Key Strategies and Developments
  - 7.11. AstraZeneca
    
    7.11.1. Company Overview
    
    7.11.2. Financial Highlights
    
    7.11.3. Product Portfolio
    
    7.11.4. SWOT Analysis
    
    7.11.5. Key Strategies and Developments
  - 7.12. Bristol-Myers Squibb
    
    7.12.1. Company Overview
    
    7.12.2. Financial Highlights
    
    7.12.3. Product Portfolio
    
    7.12.4. SWOT Analysis
    
    7.12.5. Key Strategies and Developments
  - 7.13. Conquer
    
    7.13.1. Company Overview
    
    7.13.2. Financial Highlights
    
    7.13.3. Product Portfolio
    
    7.13.4. SWOT Analysis
    
    7.13.5. Key Strategies and Developments
- 8. Assumptions and Acronyms
- 9. Research Methodology
- 10. Contact
- AstraZeneca plc.
- Mylan N.V.
- Pfizer Inc.
- Johnson & Johnson Services, Inc.
- F. Hoffmann-La Roche Ltd.
- Merck & Co., Inc.
- Bausch Health
- GlaxoSmithKline plc.
- Sun Pharmaceutical Industries Ltd.
- Bayer AG
- Eli Lily and Company
- Dr. Reddy’s Laboratories Ltd.
- Takeda Pharmaceutical Company Limited
- Other Key Players